Amneal Pharmaceuticals (AMRX) Accumulated Depreciation & Amortization (2017 - 2024)
Historic Accumulated Depreciation & Amortization for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Q4 2024 value amounting to $563.5 million.
- Amneal Pharmaceuticals' Accumulated Depreciation & Amortization rose 1092.32% to $563.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $563.5 million, marking a year-over-year increase of 1092.32%. This contributed to the annual value of $563.5 million for FY2024, which is 1092.32% up from last year.
- Per Amneal Pharmaceuticals' latest filing, its Accumulated Depreciation & Amortization stood at $563.5 million for Q4 2024, which was up 1092.32% from $508.0 million recorded in Q4 2023.
- In the past 5 years, Amneal Pharmaceuticals' Accumulated Depreciation & Amortization ranged from a high of $563.5 million in Q4 2024 and a low of $332.1 million during Q4 2020
- For the 5-year period, Amneal Pharmaceuticals' Accumulated Depreciation & Amortization averaged around $448.8 million, with its median value being $446.0 million (2022).
- As far as peak fluctuations go, Amneal Pharmaceuticals' Accumulated Depreciation & Amortization surged by 2032.06% in 2020, and later surged by 1092.32% in 2024.
- Quarter analysis of 5 years shows Amneal Pharmaceuticals' Accumulated Depreciation & Amortization stood at $332.1 million in 2020, then increased by 18.79% to $394.6 million in 2021, then increased by 13.03% to $446.0 million in 2022, then increased by 13.91% to $508.0 million in 2023, then grew by 10.92% to $563.5 million in 2024.
- Its Accumulated Depreciation & Amortization stands at $563.5 million for Q4 2024, versus $508.0 million for Q4 2023 and $446.0 million for Q4 2022.